Awareness and Knowledge of Biosimilars Among Rheumatologists and Patients
DOI:
https://doi.org/10.61919/jhrr.v5i1.1755Keywords:
Biosimilars, Rheumatology, Biologic Therapy, Patient Education, Physician Awareness, Drug Substitution, Immunotherapy,Abstract
Background: Biosimilars offer cost-effective alternatives to biologics in rheumatology; however, their adoption remains hindered by physician hesitancy and patient misconceptions. Despite increasing clinical use, knowledge gaps persist, affecting prescribing behaviors and treatment adherence. Objective: This study aimed to assess awareness, perceptions, and barriers to biosimilar adoption among rheumatologists and patients, identifying key factors influencing acceptance. Methods: A cross-sectional survey was conducted among 22 rheumatologists and 66 patients in clinical rheumatology settings. Structured questionnaires evaluated demographic characteristics, familiarity with biosimilars, prescribing patterns, and patient acceptance. Data were analyzed using SPSS v25, employing chi-square tests and t-tests to assess statistical significance, with p-values <0.05 considered significant. Results: Among rheumatologists, 80% (n=18, p=0.021) were very familiar with biosimilars, and 75% (n=16, p=0.017) had received formal education, yet only 70% (n=15, p=0.015) had prescribed them. Among patients, 60% (n=40, p=0.003) rated their biosimilar knowledge as poor, and 55% (n=36, p=0.006) were unsure about their safety and efficacy. A significant gap in physician-patient communication was observed, with 65% (n=43, p=0.008) of patients never discussing biosimilars with their rheumatologist. Conclusion: Rheumatologists demonstrated strong biosimilar knowledge, yet prescribing reluctance persisted, while patients exhibited significant uncertainty and reliance on non-medical information. Targeted education and structured communication strategies are essential to improve biosimilar adoption, ensuring cost-effective and evidence-based treatment.
Downloads
References
CastañedaHernández G, Sandoval H, Coindreau J, RodriguezDavison LF, Pineda C. Barriers towards effective pharmacovigilance systems of biosimilars in rheumatology: A Latin American survey. Pharmacoepidemiol Drug Saf. 2019;28(8):1035-44.
Colloca L, Panaccione R, Murphy TK. The Clinical Implications of Nocebo Effects for Biosimilar Therapy. Front Pharmacol. 2019;10.
D K, N B. Evaluation of Physicianstextquoteright Knowledge and Attitudes Towards Biosimilars in Russia and Issues Associated with Their Prescribing. Biomolecules. 2019.
E L, Michael W, S O, Paula G, D C. Factors Affecting Health Care Provider Knowledge and Acceptance of Biosimilar Medicines: A Systematic Review. Journal of Managed Care & Specialty Pharmacy. 2019.
Ismailov RM, Khasanova ZD, Gascon P. Knowledge and Awareness of Biosimilars among Oncology Patients in Colorado, USA. Future Oncology. 2019;15(22):2577-84.
J C, T D, Taylor O, B B. Patient Perspectives on Switching from Infliximab to Infliximabdyyb in Patients with Rheumatologic Diseases in the United States. ACR Open Rheumatology. 2019.
L F, J C, S T, M B, Audrey M, M S, et al. Patients' information and perspectives on biosimilars in rheumatology: A French nation-wide survey. Joint, bone, spine : revue du rhumatisme. 2019.
Sf. Maria'' Clinical Hospital DoR, Internal Medicine BR, Carol Davila'' University of M, Pharmacy BR, Sf. Maria'' Clinical Hospital DoR, Internal Medicine BR, et al. Patient state of knowledge on biosimilars -- do physicians need to improve education skills? 2019.
Smolen JS, Goncalves J, Quinn M, Benedetti F, Lee JY. Era of biosimilars in rheumatology: reshaping the healthcare environment. RMD Open. 2019;5(1):e000900.
A G, Dorothy M. US rheumatologiststextquoteright beliefs and knowledge about biosimilars: a survey. Rheumatology. 2020.
Almalki ZS, Iqbal MS, Alossaimi MA, Lasaf AM, Almawash BA, Aldossary FH, et al. Physicianstextquoteright Knowledge and Awareness about Biosimilars in Saudi Arabia: What is Imperative to Know ?? J Young Pharm. 2020;12(3):280-4.
Ismailov R, Simoens S, Khasanova Z. Greater awareness of biosimilars and shared decision-making among patients attending rheumatology practices in Colorado, United States: Real-world data. World Journal of Rheumatology. 2020;10(1):1-10.
Kati S, Merja M, J J, K H-A. Physicianstextquoteright perceptions of the uptake of biosimilars: a systematic review. BMJ Open. 2020.
L B, S S, A V, I H. European Stakeholder Learnings Regarding Biosimilars: Part I---Improving Biosimilar Understanding and Adoption. Biodrugs. 2020.
N B, J C, Jie H, Zeling H, Michael E, Tracy J, et al. Patterns of Tumor Necrosis Factor Inhibitor (TNFi) Biosimilar Use Across United States Rheumatology Practices. ACR Open Rheumatology. 2020.
T H, Y T, R M. Adalimumab Biosimilars in the Treatment of Rheumatoid Arthritis: A Systematic Review of the Evidence for Biosimilarity. Rheumatol Ther. 2020.
T K, S R, Dorothy W, L K, S P, S M, et al. Who is afraid of biosimilars? Openness to biosimilars in an Australian cohort of patients with rheumatoid arthritis. Internal medicine journal (Print). 2020.
Vesa H, Armond D, Katerina AN, Ljubica Š, Z B, A G. Clinical and Regulatory Concerns of Biosimilars: A Review of Literature. Int J Environ Res Public Health. 2020.
Barbier L, Vandenplas Y, Simoens S, Declerck P, Vulto AG, Huys I. Knowledge and perception of biosimilars in ambulatory care: a survey among Belgian community pharmacists and physicians. Journal of Pharmaceutical Policy and Practice. 2021;14(1).
Demir-Dora D, Aksoyalp ZŞ. Medical studentstextquoteright knowledge and awareness levels about biologics and biosimilars: the earlier the better? Expert Opin Biol Ther. 2021;22(2):245-51.
Gall S, Kiltz U, Kobylinski T, Andreica I, Vaupel K, Waldecker C, et al. Investigation of Patient Satisfaction with Education in a Biosimilar Multiswitch Scenario - A Comparison Between Rheumatologists and Nurse Specialists. 2021.
J P, K K, S K, George JG, S S, K H, et al. Oncologiststextquoteright knowledge and perspectives on the use of biosimilars. J Clin Oncol. 2021.
Samantha Y-KP, J H, Yu K, S C. Assessing Knowledge and Attitude of Healthcare Professionals on Biosimilars: A National Survey for Pharmacists and Physicians in Taiwan. Healthcare. 2021.
Vandenplas Y, Simoens S, Van Wilder P, Vulto AG, Huys I. Informing Patients about Biosimilar Medicines: The Role of European Patient Associations. Pharmaceuticals. 2021;14(2):117.
A G, Colby TE, V S. Provider and patient knowledge gaps on biosimilars: insights from surveys. Am J Manag Care. 2022.
Alannah Q, S L, C B, Samuel LW, D R, R B, et al. Attitudes of Australians with inflammatory arthritis to biologic therapy and biosimilars. Rheumatology Advances in Practice. 2022.
Carly AC, L M. A review of biosimilars for rheumatoid arthritis. Current opinion in pharmacology (Print). 2022.
S G, U K, Tanja K, I A, K V, C W, et al. Patient knowledge about biosimilars and satisfaction with the education provided by rheumatologists or nurse specialists in a biosimilar multiswitch scenario - The perception study. Semin Arthritis Rheum. 2022.
Vandenplas Y, Barbier L, Simoens S, Van Wilder P, Vulto AG, Huys I. Perceptions About Biosimilar Medicines Among Belgian Patients in the Ambulatory Care. Front Pharmacol. 2022;12.
Gibofsky A, Jacobson G, Franklin A, OtextquoterightHara-Levi S, Peyrin-Biroulet L, McGrath M, et al. An online survey among US patients with immune-mediated conditions: Attitudes about biosimilars. Journal of Managed Care & Specialty Pharmacy. 2023;29(4):343-9.
Carly G, Jessica M, Casey F, Brandon H, Amber S, Amy E, et al. Biosimilar perceptions among autoimmune prescribers and pharmacists in health system specialty pharmacy. Journal of Managed Care & Specialty Pharmacy. 2024.
Supat T, Anupam D, Pravin P, M L, Lyndon L, James W. Physicians' and patients' perception of biosimilars and factors affecting biosimilar prescribing in selected Asian Countries: a survey study. Expert Opin Biol Ther. 2024.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Muhammad Shiraz Niaz, Sana Suhail, Usama Mahmood
This work is licensed under a Creative Commons Attribution 4.0 International License.
Public Licensing Terms
This work is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). Under this license:
- You are free to share (copy and redistribute the material in any medium or format) and adapt (remix, transform, and build upon the material) for any purpose, including commercial use.
- Attribution must be given to the original author(s) and source in a manner that is reasonable and does not imply endorsement.
- No additional restrictions may be applied that conflict with the terms of this license.
For more details, visit: https://creativecommons.org/licenses/by/4.0/.
